BIO-TECHNE Corp APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
BIO-TECHNE Corp (TECH) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $858.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-08-24
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $297.00K.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $190.00K, a 442.86% increase year-over-year.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-12-31 was $373.00K, a 0.00% change year-over-year.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-09-30 was -$2.00K, a 105.26% decline year-over-year.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2026 was $858.00K, a 4.00% increase from fiscal 2025.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $825.00K, a 8.94% decline from fiscal 2024.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $906.00K, a 0.98% decline from fiscal 2023.
- BIO-TECHNE Corp apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $915.00K, a 5.96% decline from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $297.00K derived: 10-K 12 month − 3 quarters · filed 2026-08-24 | $487.00K derived: sum of 2 quarters · filed 2026-08-24 | $860.00K derived: sum of 3 quarters · filed 2026-08-24 | $858.00K 10-K · filed 2026-08-24 |
| 2026-03-31 | $190.00K 10-Q · filed 2026-05-06 | $563.00K derived: sum of 2 quarters · filed 2026-05-06 | $561.00K derived: sum of 3 quarters · filed 2026-05-06 | |
| 2025-12-31 | $373.00K 10-Q · filed 2026-05-06 | $371.00K derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2025-09-30 | -$2.00K 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $825.00K 10-K · filed 2026-08-24 | |||
| 2025-03-31 | $35.00K 10-Q · filed 2026-05-06 | $408.00K derived: sum of 2 quarters · filed 2026-05-06 | $446.00K derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $373.00K 10-Q · filed 2026-05-06 | $411.00K derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-09-30 | $38.00K 10-Q · filed 2026-05-06 | |||
| 2024-06-30 | $906.00K 10-K · filed 2026-08-24 | |||
| 2024-03-31 | $80.00K 10-Q · filed 2025-05-08 | $420.00K derived: sum of 2 quarters · filed 2025-05-08 | $532.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $340.00K 10-Q · filed 2025-05-08 | $452.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-09-30 | $112.00K 10-Q · filed 2025-05-08 | |||
| 2023-06-30 | $915.00K 10-K · filed 2025-08-22 | |||
| 2023-03-31 | $113.00K 10-Q · filed 2024-05-06 | $446.00K derived: sum of 2 quarters · filed 2024-05-06 | $543.00K derived: sum of 3 quarters · filed 2024-05-06 | |
| 2022-12-31 | $333.00K 10-Q · filed 2024-05-06 | $430.00K derived: sum of 2 quarters · filed 2024-05-06 | ||
| 2022-09-30 | $97.00K 10-Q · filed 2024-05-06 | |||
| 2022-06-30 | $973.00K 10-K · filed 2024-08-22 | |||
| 2022-03-31 | $25.00K 10-Q · filed 2023-05-08 | $292.00K derived: sum of 2 quarters · filed 2023-05-08 | $633.00K derived: sum of 3 quarters · filed 2023-05-08 | |
| 2021-12-31 | $267.00K 10-Q · filed 2023-05-08 | $608.00K derived: sum of 2 quarters · filed 2023-05-08 | ||
| 2021-09-30 | $341.00K 10-Q · filed 2023-05-08 | |||
| 2021-06-30 | $917.00K 10-K · filed 2023-08-23 | |||
| 2021-03-31 | $411.00K 10-Q · filed 2022-05-09 | $517.00K derived: sum of 2 quarters · filed 2022-05-09 | $803.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $106.00K 10-Q · filed 2022-05-09 | $392.00K derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2020-09-30 | $286.00K 10-Q · filed 2022-05-09 | |||
| 2020-06-30 | $435.00K 10-K · filed 2022-08-24 | |||
| 2020-03-31 | $110.00K 10-Q · filed 2021-05-07 | $222.00K derived: sum of 2 quarters · filed 2021-05-07 | $321.00K derived: sum of 3 quarters · filed 2021-05-07 | |
| 2019-12-31 | $112.00K 10-Q · filed 2021-05-07 | $211.00K derived: sum of 2 quarters · filed 2021-05-07 | ||
| 2019-09-30 | $99.00K 10-Q · filed 2021-05-07 | |||
| 2019-06-30 | $505.00K 10-K · filed 2021-08-25 | |||
| 2019-03-31 | $84.00K 10-Q · filed 2020-05-11 | $161.00K derived: sum of 2 quarters · filed 2020-05-11 | $399.00K derived: sum of 3 quarters · filed 2020-05-11 | |
| 2018-12-31 | $77.00K 10-Q · filed 2020-05-11 | $315.00K derived: sum of 2 quarters · filed 2020-05-11 | ||
| 2018-09-30 | $238.00K 10-Q · filed 2020-05-11 | |||
| 2018-06-30 | $281.00K 10-K · filed 2020-08-26 | |||
| 2018-03-31 | $78.00K 10-Q · filed 2019-05-07 | $137.00K derived: sum of 2 quarters · filed 2019-05-07 | $214.00K derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $59.00K 10-Q · filed 2019-05-07 | $136.00K derived: sum of 2 quarters · filed 2019-05-07 | ||
| 2017-09-30 | $77.00K 10-Q · filed 2019-05-07 | |||
| 2017-06-30 | $213.00K 10-K/A · filed 2019-11-06 | |||
| 2016-06-30 | $144.00K 10-K · filed 2018-08-27 | |||
| 2015-06-30 | $39.00K 10-K · filed 2017-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |